<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02693535</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00014171</org_study_id>
    <nct_id>NCT02693535</nct_id>
  </id_info>
  <brief_title>TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer</brief_title>
  <acronym>TAPUR</acronym>
  <official_title>Targeted Agent and Profiling Utilization Registry (TAPUR) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American Society of Clinical Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>American Society of Clinical Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to learn from the real world practice of prescribing targeted&#xD;
      therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be&#xD;
      a drug target or to predict sensitivity to a drug.&#xD;
&#xD;
      NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant&#xD;
      biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest&#xD;
      participating TAPUR site (see participating centers).&#xD;
&#xD;
      *********************************************************************************************&#xD;
      *********************************************************************************&#xD;
&#xD;
      Results in publication or poster presentation format are posted as they become available for&#xD;
      individual cohorts at www.tapur.org/news. The results may be accessed at any time. All&#xD;
      results will be made available on clinicaltrials.gov at the end of the study. Indexing of&#xD;
      available results on PubMed is in progress.&#xD;
&#xD;
      *********************************************************************************************&#xD;
      *********************************************************************************&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized&#xD;
      clinical trial that aims to describe the safety and efficacy of commercially available,&#xD;
      targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has&#xD;
      a potentially actionable genomic variant. TAPUR will study Food and Drug Administration&#xD;
      (FDA)-approved targeted therapies that are contributed by collaborating pharmaceutical&#xD;
      companies, catalogue the choice of molecular profiling test by clinical oncologists and&#xD;
      develop hypotheses for additional clinical trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria</measure>
    <time_frame>Assessed at 16 weeks of treatment</time_frame>
    <description>Each cohort includes participants with the same tumor type, genomic variant and study drug. For solid tumors, the Response Evaluation Criteria for Solid Tumors (RECIST) criteria will be used, for non-Hodgkin Lymphoma, the Lugano Criteria will be used, and for multiple myeloma, the International Uniform Response Criteria for Multiple Myeloma will be used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Duration of survival from registration on study until death from any cause, assessed throughout end of study, up to 3 years</time_frame>
    <description>OS will be estimated using the Kaplan-Meier method</description>
  </secondary_outcome>
  <number_of_arms>18</number_of_arms>
  <enrollment type="Anticipated">3581</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Group 3 (ALK, ROS1, MET)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants receive crizotinib - dosage, frequency and duration per label; acceptable genomic matches include ALK fusion or mutation, ROS1 fusion, MET amplification or mutation, MET exon 14 alteration, RON amplification or mutation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 (CDKN2A, CDK4, CDK6)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants receive palbociclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5 (CSF1R,PDGFR,VEGFR)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants receive sunitinib - dosage, frequency and duration per label; acceptable genomic matches include CSF1R, PDGFR, VEGFR1/2/3, KIT, FLT-3, RET, FGFR1/2/3, VHL amplifications or mutations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6 (mTOR, TSC)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants receive temsirolimus - dosage, frequency and duration per label; acceptable genomic matches include mTOR, TSC1/2, AKT1 mutations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 8 (ERBB2)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants receive trastuzumab and pertuzumab - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 9 (BRAF V600E/D/K/R)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants receive vemurafenib and cobimetinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600E/D/K/R mutations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 13 (RET,VEGFR1/2/3,KIT,PDGFRβ,RAF-1,BRAF)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants receive regorafenib - dosage, frequency and duration per label; acceptable genomic matches include RET, VEGFR1/2/3, KIT, PDGFRβ, RAF-1, BRAF mutations or amplifications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 14 (BRCA1/2; ATM)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants receive olaparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 inactivating mutations; ATM mutations or deletions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 15 (POLE, POLD1)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants receive pembrolizumab - dosage, frequency and duration per label; acceptable genomic matches include specific POLE and POLD1 mutations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 16 (MSI-H, high mutational load and others)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants receive nivolumab and ipilimumab - dosage, frequency and duration per label; acceptable genomic matches include MSI high status, high tumor mutational burden, MLH1, MSH2/6, PMS2, EPCAM mutations, specific POLE or POLD1 mutations, BRCA1/2, ATM, MSH3, PMS1, MLH3, EXO1, RFC1/2/3/4/5, PCNA, RPA1/2/3/4, and SSBP1 loss of function mutations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 17 (CDKN2A, CDK4, CDK6)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants receive abemaciclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 18 (NRG1)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants receive afatinib - dosage, frequency and duration per label; acceptable genomic matches include NRG1 fusions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 19 (BRCA1/2, PALB2)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants receive talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 and PALB2 mutations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 20 (ERBB2)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants receive atezolizumab plus PHESGO - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 21 (BRCA1/2, PALB2, ATM, and others)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants receive atezolizumab plus talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic mutations in BRCA1/2, PALB2, ATM, ATR, CHEK2, FANCA, RAD51C, NBN, MLH1, MRE11A, CDK12; positive genomic instability score reported on the Myriad MyChoice CDx test; or Genomic Loss of Heterozygosity (LOH) Score above threshold as reported on a FoundationOne CDx test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 22 (ROS1 fusion)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants receive entrectinib - dosage, frequency and duration per label; acceptable genomic matches include any ROS1 fusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 23 (NTRK amplification)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants receive larotrectinib - dosage, frequency and duration per label; acceptable genomic matches include NTRK1/2/3 amplification</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 24 (ERBB2)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants receive tucatinib plus trastuzumab SC - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crizotinib</intervention_name>
    <description>drug</description>
    <arm_group_label>Group 3 (ALK, ROS1, MET)</arm_group_label>
    <other_name>Xalkori</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>drug</description>
    <arm_group_label>Group 4 (CDKN2A, CDK4, CDK6)</arm_group_label>
    <other_name>Ibrance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>drug</description>
    <arm_group_label>Group 5 (CSF1R,PDGFR,VEGFR)</arm_group_label>
    <other_name>Sutent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temsirolimus</intervention_name>
    <description>drug</description>
    <arm_group_label>Group 6 (mTOR, TSC)</arm_group_label>
    <other_name>Torisel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab and Pertuzumab</intervention_name>
    <description>drug</description>
    <arm_group_label>Group 8 (ERBB2)</arm_group_label>
    <other_name>Herceptin and Perjeta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vemurafenib and Cobimetinib</intervention_name>
    <description>drug</description>
    <arm_group_label>Group 9 (BRAF V600E/D/K/R)</arm_group_label>
    <other_name>Zelboraf and Cotellic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib</intervention_name>
    <description>drug</description>
    <arm_group_label>Group 13 (RET,VEGFR1/2/3,KIT,PDGFRβ,RAF-1,BRAF)</arm_group_label>
    <other_name>Stivarga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib</intervention_name>
    <description>drug</description>
    <arm_group_label>Group 14 (BRCA1/2; ATM)</arm_group_label>
    <other_name>Lynparza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>drug</description>
    <arm_group_label>Group 15 (POLE, POLD1)</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab and Ipilimumab</intervention_name>
    <description>drug</description>
    <arm_group_label>Group 16 (MSI-H, high mutational load and others)</arm_group_label>
    <other_name>Opdivo and Yervoy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abemaciclib</intervention_name>
    <description>drug</description>
    <arm_group_label>Group 17 (CDKN2A, CDK4, CDK6)</arm_group_label>
    <other_name>Verzenio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib</intervention_name>
    <description>drug</description>
    <arm_group_label>Group 18 (NRG1)</arm_group_label>
    <other_name>Gilotrif</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talazoparib</intervention_name>
    <description>drug</description>
    <arm_group_label>Group 19 (BRCA1/2, PALB2)</arm_group_label>
    <other_name>Talzenna</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab and PHESGO</intervention_name>
    <description>drug</description>
    <arm_group_label>Group 20 (ERBB2)</arm_group_label>
    <other_name>Tecentriq and PHESGO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab and Talazoparib</intervention_name>
    <description>drug</description>
    <arm_group_label>Group 21 (BRCA1/2, PALB2, ATM, and others)</arm_group_label>
    <other_name>Tecentriq and Talzenna</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entrectinib</intervention_name>
    <description>drug</description>
    <arm_group_label>Group 22 (ROS1 fusion)</arm_group_label>
    <other_name>Rozlytrek</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Larotrectinib</intervention_name>
    <description>drug</description>
    <arm_group_label>Group 23 (NTRK amplification)</arm_group_label>
    <other_name>Vitrakvi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tucatinib plus Trastuzumab Subcutaneous (SC)</intervention_name>
    <description>drug</description>
    <arm_group_label>Group 24 (ERBB2)</arm_group_label>
    <other_name>Tukysa and Herceptin Hylecta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  12 years of age or older (*Restrictions apply. Not all therapies are available for&#xD;
             patients &lt;18)&#xD;
&#xD;
          -  Histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or&#xD;
             B cell non-Hodgkin lymphoma who is no longer benefiting from standard anti-cancer&#xD;
             treatment or for whom, in the opinion of the treating physician, no such treatment is&#xD;
             available or indicated&#xD;
&#xD;
          -  Performance status 0-2 (Per Eastern Cooperative Oncology Group (ECOG) criteria)&#xD;
&#xD;
          -  Patients must have acceptable organ function as defined below. However, as noted&#xD;
             above, drug-specific inclusion/exclusion criteria specified in the protocol appendix&#xD;
             for each agent will take precedence for this and all inclusion criteria:&#xD;
&#xD;
               1. Absolute neutrophil count ≥ 1.5 x 106/µl&#xD;
&#xD;
               2. Hemoglobin &gt; 9.0 g/dl&#xD;
&#xD;
               3. Platelets &gt; 75,000/µl&#xD;
&#xD;
               4. Total bilirubin &lt; 2.0 mg/ dl, except in patients with Gilbert's Syndrome&#xD;
&#xD;
               5. Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT)&#xD;
                  and alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) &lt;&#xD;
                  2.5 x institutional upper limit of normal (ULN) (or &lt; 5 x ULN in patients with&#xD;
                  known hepatic metastases)&#xD;
&#xD;
               6. Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50&#xD;
                  mL/min/1.73 m2&#xD;
&#xD;
          -  Patients must have disease that can be objectively measured by physicial or&#xD;
             radiographic exam or evaluable disease (per RECIST v1.1 for solid tumor, Lugano&#xD;
             criteria for non Hodgkin lymphoma or International Myeloma Working Group criteria for&#xD;
             multiple myeloma), defined as at least one lesion that can be accurately measured in&#xD;
             at least one dimension (longest diameter to be recorded for non-nodal lesions and&#xD;
             short axis for nodal lesions) as ≥20 mm with conventional techniques or as ≥10 mm with&#xD;
             spiral computed tomography (CT) scan, Magnetic Resonance Imaging (MRI), or a&#xD;
             subcutaneous or superficial lesion that can be measured with calipers by clinical&#xD;
             exam. For lymph nodes, the short axis must be ≥15 mm. Patients who have assessable&#xD;
             disease by physical or radiographic examination but do not meet these definitions of&#xD;
             measurable disease are eligible and will be considered to have evaluable disease.&#xD;
             Patient's whose disease cannot be objectively measured by physical or radiographic&#xD;
             examination (e.g., elevated serum tumor marker only, bone-only disease without an&#xD;
             identifiable soft tissue component, or patients with only assessable non-measurable&#xD;
             disease) are NOT eligible.&#xD;
&#xD;
          -  Results must be available from a genomic test or immunohistochemistry (IHC) test for&#xD;
             protein expression performed in a Clinical Laboratory Improvement Amendments&#xD;
             (CLIA)-certified and College of American Pathologists (CAP)-accredited or New York&#xD;
             State accredited (for labs offering services to residents of NY) laboratory. Labs that&#xD;
             have registered the test with the NIH Genetic Testing Registry or that provide a&#xD;
             report that has been designated as optimized for TAPUR participation are preferred,&#xD;
             but not required. The genomic or IHC test used to qualify a patient for participation&#xD;
             in TAPUR may have been performed on any specimen of the patient's tumor obtained at&#xD;
             any point during the patient's care at the discretion of the patient's treating&#xD;
             physician. Genomic assays performed on cell-free DNA in plasma (&quot;liquid biopsies&quot;)&#xD;
             will also be acceptable if the genomic analysis is performed in a laboratory that&#xD;
             meets the criteria described above.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent/assent&#xD;
             document.&#xD;
&#xD;
          -  Have a tumor genomic profile for which single agent treatment with one of the FDA&#xD;
             approved targeted anti-cancer drugs included in this study has potential clinical&#xD;
             benefit based on the criteria described in protocol.&#xD;
&#xD;
          -  For orally administered drugs, the patient must be able to swallow and tolerate oral&#xD;
             medication and must have no known malabsorption syndrome.&#xD;
&#xD;
          -  Because of the risks of drug treatment to the developing fetus, women of child-bearing&#xD;
             potential and men must agree to use adequate contraception (hormonal or barrier method&#xD;
             of birth control; abstinence) for the duration of study participation, and for four&#xD;
             months following completion of study therapy. Should a woman become pregnant or&#xD;
             suspect she is pregnant while participating in this study or if she is the partner of&#xD;
             a male participant in this study and becomes pregnant while he is participating in&#xD;
             this study, she should inform her or her partner's treating physician immediately as&#xD;
             well as her obstetrician. Female study patients who become pregnant must immediately&#xD;
             discontinue treatment with any study therapy. Male patients should avoid impregnating&#xD;
             a female partner. Male study patients, even if surgically sterilized, (i.e.&#xD;
             post-vasectomy) must agree to one of the following: practice effective barrier&#xD;
             contraception during the entire study treatment period and for a specified amount of&#xD;
             time the last dose of study drug, or completely abstain from sexual intercourse.&#xD;
&#xD;
        Note: TAPUR does not explicitly exclude any type of solid tumor, but the patient must have&#xD;
        measurable and evaluable disease per RECIST v1.1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients whose disease is not measurable or cannot be assessed by radiographic imaging&#xD;
             or physical examination (e.g., elevated serum tumor marker only) are not eligible&#xD;
&#xD;
          -  Patients with primary brain tumors or leptomeningeal metastases are excluded.&#xD;
&#xD;
          -  Patients with previously treated brain metastases are eligible, provided that the&#xD;
             patient has not experienced a seizure or had a clinically significant change in&#xD;
             neurological status within the 3 months prior to registration. All patients with&#xD;
             previously treated brain metastases must be clinically stable for at least 1 month&#xD;
             after completion of treatment and off steroid treatment for one month prior to study&#xD;
             enrollment.&#xD;
&#xD;
          -  Patients with known progressive brain metastases are eligible but additional&#xD;
             eligibility criteria apply.&#xD;
&#xD;
        Note: there are additional exclusion criteria that may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pam Mangat, MS</last_name>
    <phone>www.tapur.org</phone>
    <email>pam.mangat@asco.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Ross, RN, OCN</last_name>
      <phone>205-975-0103</phone>
      <email>tross@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Eddy Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America-Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85338</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Coats, MS, RN, CCRC</last_name>
      <phone>623-207-3899</phone>
      <email>jessica.coats@ctca-hope.com</email>
    </contact>
    <investigator>
      <last_name>Ashish Sangal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sutter Auburn</name>
      <address>
        <city>Auburn</city>
        <state>California</state>
        <zip>95602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Babski</last_name>
      <phone>916-878-4990</phone>
      <email>BabskiK@sutterhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sutter Alta Bates</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivian Leong, RN</last_name>
      <phone>510-204-3428</phone>
      <email>leongv@sutterhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saba Mukarram</last_name>
      <phone>310-231-2181</phone>
      <email>smukarram@theangelesclinic.org</email>
    </contact>
    <investigator>
      <last_name>Omid Hamid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sutter Palo Alto Medical Foundation: Palo Alto</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrials@pamf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sutter Roseville</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Babski</last_name>
      <phone>916-878-4990</phone>
      <email>BabskiK@sutterhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sutter Sacramento</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Rodrigues-Fong</last_name>
      <phone>916-454-6628</phone>
      <email>RodrigI@sutterhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center Research Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>415-600-1654</phone>
      <email>clinicalresearch@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Deepti Behl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sutter Cancer Research Consortium</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurel Brechtel</last_name>
      <phone>415-600-1654</phone>
      <email>BrechtLa@cpmcri.org</email>
    </contact>
    <investigator>
      <last_name>Stacy D'Andre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sutter Palo Alto Medical Foundation: Santa Cruz</name>
      <address>
        <city>Santa Cruz</city>
        <state>California</state>
        <zip>95065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrials@pamf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sutter Palo Alto Medical Foundation: Fremont</name>
      <address>
        <city>Santa Cruz</city>
        <state>California</state>
        <zip>994538</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrials@pamf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sutter Palo Alto Medical Foundation: Sunnyvale</name>
      <address>
        <city>Sunnyvale</city>
        <state>California</state>
        <zip>94086</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinicaltrials@pamf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Couch</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Tareq Al Baghdadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolina Troche, BS</last_name>
      <phone>305-243-1481</phone>
      <email>cxt582@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Carmen Calfa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America - Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mittie Mitchell, RN</last_name>
      <phone>770-400-7194</phone>
      <email>Mittie.Mitchell@ctca-hope.com</email>
    </contact>
    <investigator>
      <last_name>Herbert L. Duvivier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Somini John</last_name>
      <phone>404-778-7664</phone>
      <email>somini.m.john@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Olatunji Alese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gynecologic Oncology and Surgical Specialists at the Lewis Cancer &amp; Research Pavilion</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Smith, RN, MSN, OCN</last_name>
      <phone>912-819-5723</phone>
      <email>smiths1@sjchs.org</email>
    </contact>
    <investigator>
      <last_name>Mark Taylor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lewis Cancer &amp; Research Pavilion at the Melanoma, Skin Cancer &amp; Sarcoma Institute</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Smith, RN, MSN, OCN</last_name>
      <phone>912-819-5723</phone>
      <email>smiths1@sjchs.org</email>
    </contact>
    <investigator>
      <last_name>Mark Taylor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lewis Cancer &amp; Research Pavilion</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Smith, RN, MSN, OCN</last_name>
      <phone>912-819-5723</phone>
      <email>smiths1@sjchs.org</email>
    </contact>
    <investigator>
      <last_name>Mark Taylor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summit Cancer Care</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Smith, RN, MSN, OCN</last_name>
      <phone>912-819-5723</phone>
      <email>smiths1@sjchs.org</email>
    </contact>
    <investigator>
      <last_name>Mark Taylor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Queen's Medical Center (The University of Texas MD Anderson Cancer Center)</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Eckert, MPH</last_name>
      <phone>713-745-8074</phone>
      <email>ACEckert@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Funda Meric-Bernstam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America-Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60099</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anjanette Sorensen, BSN, RN</last_name>
      <phone>847-872-4701</phone>
      <email>anjanette.sorensen@ctca-hope.com</email>
    </contact>
    <investigator>
      <last_name>Eugene Ahn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Health Network (The University of Texas MD Anderson Cancer Center)</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Eckert, MPH</last_name>
      <phone>713-745-8074</phone>
      <email>ACEckert@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Funda Meric-Bernstam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harold Alfond Center for Cancer Care</name>
      <address>
        <city>Augusta</city>
        <state>Maine</state>
        <zip>04330</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Neptune, BSN, RN</last_name>
      <phone>207-626-4811</phone>
      <email>sandra.neptune@mainegeneral.org</email>
    </contact>
    <investigator>
      <last_name>Rachit Kumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jackson Laboratory - Maine Cancer Genomics Initiative</name>
      <address>
        <city>Augusta</city>
        <state>Maine</state>
        <zip>04330</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Helbig, CCRP</last_name>
      <phone>207-664-4659</phone>
      <email>Petra.Helbig@jax.org</email>
    </contact>
    <investigator>
      <last_name>Jens Rueter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Waldo County General Hospital</name>
      <address>
        <city>Belfast</city>
        <state>Maine</state>
        <zip>04915</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jen Dalton, MHA, BSN, RN</last_name>
      <phone>207-294-8291</phone>
      <email>JDalton@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Roger Inhorn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SMHC Cancer Care and Blood Disorders -Biddeford</name>
      <address>
        <city>Biddeford</city>
        <state>Maine</state>
        <zip>04005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jen Dalton</last_name>
      <phone>207-294-8291</phone>
      <email>JDalton@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Roger Inhorn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northern Light Cancer Care</name>
      <address>
        <city>Brewer</city>
        <state>Maine</state>
        <zip>04412</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Mancini, MHA, BSN, RN</last_name>
      <phone>207-973-5581</phone>
      <email>cmancini@northernlight.org</email>
    </contact>
    <investigator>
      <last_name>Sarah Sinclair, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Raish Peavey Haskell Children's Cancer and Treatment Center</name>
      <address>
        <city>Brewer</city>
        <state>Maine</state>
        <zip>04412</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla C Mancini, RN, BSN, OCN</last_name>
      <phone>207-973-5581</phone>
      <email>cmancini@northernlight.org</email>
    </contact>
    <investigator>
      <last_name>Sarah Sinclair, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MaineHealth Cancer Care -Brunswick</name>
      <address>
        <city>Brunswick</city>
        <state>Maine</state>
        <zip>04011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jen Dalton, MHA, BSN, RN</last_name>
      <phone>207-294-8291</phone>
      <email>JDalton@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Roger Inhorn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New England Cancer Specialist</name>
      <address>
        <city>Kennebunk</city>
        <state>Maine</state>
        <zip>04043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia C Collins</last_name>
      <phone>207-303-3422</phone>
      <email>collip@newecs.org</email>
    </contact>
    <investigator>
      <last_name>Christian Thomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>York Hopsital Oncology &amp; Infusion Care in Kittery</name>
      <address>
        <city>Kittery</city>
        <state>Maine</state>
        <zip>03904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda i Kiberd, RN</last_name>
      <phone>207-361-6115</phone>
      <email>Brenda.Kiberd@yorkhospital.com</email>
    </contact>
    <investigator>
      <last_name>Marilyn McLaughlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stephens Memorial Hospital</name>
      <address>
        <city>Norway</city>
        <state>Maine</state>
        <zip>04268</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jen Dalton, MHA, BSN, RN</last_name>
      <phone>207-294-8291</phone>
      <email>JDalton@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Roger Inhorn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penobscot Bay Medical Center</name>
      <address>
        <city>Rockport</city>
        <state>Maine</state>
        <zip>04856</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jen Dalton, MHA, BSN, RN</last_name>
      <phone>207-294-8291</phone>
      <email>JDalton@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Roger Inhorn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SMHC Cancer Care and Blood Disorders -Sandford</name>
      <address>
        <city>Sanford</city>
        <state>Maine</state>
        <zip>04073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jen Dalton, MHA, BSN, RN</last_name>
      <phone>207-294-8291</phone>
      <email>JDalton@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Roger Inhorn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Children's Cancer Program</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jen Dalton, MHA, BSN, RN</last_name>
      <phone>207-294-8291</phone>
      <email>JDalton@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Roger Inhorn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Medical Partner's Women's Health</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jen Dalton, MHA, BSN, RN</last_name>
      <phone>207-294-8291</phone>
      <email>JDalton@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Roger Inhorn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New England Cancer Specialist</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Collins, BA, CCRC</last_name>
      <phone>207-303-3422</phone>
      <email>collip@newecs.org</email>
    </contact>
    <investigator>
      <last_name>Christian Thomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MaineHealth Cancer Care -South Portland</name>
      <address>
        <city>South Portland</city>
        <state>Maine</state>
        <zip>04106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jen Dalton, MHA, BSN, RN</last_name>
      <phone>207-294-8291</phone>
      <email>JDalton@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Roger Inhorn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New England Cancer Specialist</name>
      <address>
        <city>Topsham</city>
        <state>Maine</state>
        <zip>04086</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia C Collins, BA, CCRC</last_name>
      <phone>207-303-3422</phone>
      <email>collip@newecs.org</email>
    </contact>
    <investigator>
      <last_name>Christian Thomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>York Hospital Oncology &amp; Infusion Care in Wells</name>
      <address>
        <city>Wells</city>
        <state>Maine</state>
        <zip>04090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Kiberd, RN</last_name>
      <phone>207-361-6115</phone>
      <email>Brenda.Kiberd@yorkhospital.com</email>
    </contact>
    <investigator>
      <last_name>Marilyn McLaughlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>York Hospital Oncology &amp; Infusion Care in York</name>
      <address>
        <city>York</city>
        <state>Maine</state>
        <zip>03909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda i Kiberd, RN</last_name>
      <phone>207-361-6115</phone>
      <email>Brenda.Kiberd@yorkhospital.com</email>
    </contact>
    <investigator>
      <last_name>Marilyn McLaughlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer AnswerLine Nurses</last_name>
      <phone>800-865-1125</phone>
      <email>canceranswerline@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Ajjai Alva, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy - Brighton</name>
      <address>
        <city>Brighton</city>
        <state>Michigan</state>
        <zip>48114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Couch, BS</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Tareq Al Baghdadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy - Canton</name>
      <address>
        <city>Canton</city>
        <state>Michigan</state>
        <zip>48188</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Couch, BS</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Tareq Al Baghdadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy - Chelsea</name>
      <address>
        <city>Chelsea</city>
        <state>Michigan</state>
        <zip>48118-1370</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Couch</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Tareq Al Baghdadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ascension St. John Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Couch</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Tareq Al Baghdadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Genesys Hurley Cancer Institute</name>
      <address>
        <city>Grand Blanc</city>
        <state>Michigan</state>
        <zip>48439</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Couch, BS</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Tareq Al Baghdadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Research Consortium of West Michigan</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Connie Szczepanek, RN</last_name>
      <phone>616-391-1230</phone>
      <email>crcwm-regulatory@crcwm.org</email>
    </contact>
    <investigator>
      <last_name>Kathleen J. Yost, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sparrow Hospital</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Couch, BS</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Tareq Al Baghdadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Mary Mercy Hospital</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <zip>48154</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Couch, BS</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Tareq Al Baghdadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy Hospital Oakland</name>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <zip>48341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Couch, BS</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Tareq Al Baghdadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ascension St. Mary's Hospital</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ascension St. M Hospital, BS</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Tareq Al Baghdadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michigan Cancer Research Consortium</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <zip>48341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth LaVasseur, RN, MS</last_name>
      <phone>734-712-5658</phone>
      <email>Beth.LaVasseur@stjoeshealth.org</email>
    </contact>
    <contact_backup>
      <phone>877-590-5995</phone>
    </contact_backup>
    <investigator>
      <last_name>Philip Stella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. John Macomb Oakland Hospital</name>
      <address>
        <city>Warren</city>
        <state>Michigan</state>
        <zip>48093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Couch, BS</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Tareq Al Baghdadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandie Booker, RN, BSN, OCN</last_name>
      <phone>402-559-8197</phone>
      <email>brandie.booker@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Alissa Marr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NH Oncology - Hematology, PA</name>
      <address>
        <city>Concord</city>
        <state>New Hampshire</state>
        <zip>03103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Fleury</last_name>
      <phone>603-314-6888</phone>
      <email>A.Fleury@nhoh.com</email>
    </contact>
    <investigator>
      <last_name>Douglas Weckstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Solinsky Center for Cancer Care</name>
      <address>
        <city>Manchester</city>
        <state>New Hampshire</state>
        <zip>03103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Fleury, BA, CCRP</last_name>
      <phone>603-314-6888</phone>
      <email>A.Fleury@nhoh.com</email>
    </contact>
    <investigator>
      <last_name>Douglas Weckstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New England Cancer Specialist</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>03801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia C Collins, BA, CCRC</last_name>
      <phone>207-303-3422</phone>
      <email>collip@newecs.org</email>
    </contact>
    <investigator>
      <last_name>Christian Thomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atrium Health's Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Bumgarner, RN, CCRP</last_name>
      <phone>704-403-2520</phone>
      <email>Kelly.Bumgarner@atriumhealth.org</email>
    </contact>
    <investigator>
      <last_name>Kathryn F. Mileham, MD, FACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Health- Bismarck</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Kurniali, MD</last_name>
      <phone>701-323-5741</phone>
      <email>peter.kurniali@sanfordhealth.org</email>
    </contact>
    <investigator>
      <last_name>Peter Kurniali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Health- Fargo</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anu Gaba, MD</last_name>
      <phone>701-234-6161</phone>
      <email>anu.gaba@sanfordhealth.org</email>
    </contact>
    <investigator>
      <last_name>Anu Gaba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kettering Health</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Dymacek, BSN, RN</last_name>
      <phone>937-395-8367</phone>
      <email>allison.dymacek@ketteringhealth.org</email>
    </contact>
    <investigator>
      <last_name>Malek Safa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Health &amp; Services</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Pomeroy, RN, BSN, OCN</last_name>
      <phone>503-215-2714</phone>
      <email>Melissa.Pomeroy@providence.org</email>
    </contact>
    <investigator>
      <last_name>Walter Urba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Couch, BS</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Tareq Al Baghdadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fathima S Sheriff</last_name>
      <phone>215-728-4094</phone>
      <email>fathima.sheriff@fccc.edu</email>
    </contact>
    <investigator>
      <last_name>Margaret von Mehren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SC Cancer Specialists at St. Joseph's/Candler Bluffton</name>
      <address>
        <city>Bluffton</city>
        <state>South Carolina</state>
        <zip>29910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Smith, RN, MSN, OCN</last_name>
      <phone>912-819-5723</phone>
      <email>smiths1@sjchs.org</email>
    </contact>
    <investigator>
      <last_name>Mark Taylor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stephanie Joseph's/Candler Smith</name>
      <address>
        <city>Bluffton</city>
        <state>South Carolina</state>
        <zip>29910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Smith, RN, MSN, OCN</last_name>
      <phone>912-819-5723</phone>
      <email>smiths1@sjchs.org</email>
    </contact>
    <investigator>
      <last_name>Mark Taylor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summit Cancer Care at St. Josph's/Candler Bluffton</name>
      <address>
        <city>Bluffton</city>
        <state>South Carolina</state>
        <zip>29910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Smith, RN, MSN, OCN</last_name>
      <phone>912-819-5723</phone>
      <email>smiths1@sjchs.org</email>
    </contact>
    <investigator>
      <last_name>Mark Taylor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Carolina Cancer Specialists</name>
      <address>
        <city>Hilton Head Island</city>
        <state>South Carolina</state>
        <zip>29926</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Smith, RN, MSN, OCN</last_name>
      <phone>912-819-5723</phone>
      <email>smiths1@sjchs.org</email>
    </contact>
    <investigator>
      <last_name>Mark Taylor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Cancer Center Oncology Clinic and Pharmacy</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Powell, MD</last_name>
      <phone>605-328-5000</phone>
      <email>steven.powell@sanfordhealth.org</email>
    </contact>
    <investigator>
      <last_name>Steven Powell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Eckert, MPH</last_name>
      <phone>713-745-8074</phone>
      <email>ACEckert@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Funda Meric-Bernstam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intermountain Healthcare</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Taylor</last_name>
      <phone>801-507-3953</phone>
      <email>tracy.taylor@imail.org</email>
    </contact>
    <contact_backup>
      <last_name>Angi Kahrs, CCRP</last_name>
      <phone>435-251-4742</phone>
      <email>Angi.Cox@imail.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ramya Thota, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Derrick Haslem, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inova Schar Cancer Institute</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsey Tishman, MHA, CCRC</last_name>
      <phone>703-970-6488</phone>
      <email>lindsey.tishman@inova.org</email>
    </contact>
    <investigator>
      <last_name>Timothy Cannon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leah Clemente</last_name>
      <phone>206-386-2227</phone>
      <email>Leah.Clemente@swedish.org</email>
    </contact>
    <investigator>
      <last_name>Philip Gold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 11, 2016</study_first_submitted>
  <study_first_submitted_qc>February 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2016</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>off-label</keyword>
  <keyword>precision medicine</keyword>
  <keyword>targeted therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Olaparib</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
    <mesh_term>Afatinib</mesh_term>
    <mesh_term>Vemurafenib</mesh_term>
    <mesh_term>Crizotinib</mesh_term>
    <mesh_term>Talazoparib</mesh_term>
    <mesh_term>Tucatinib</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Entrectinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

